Effects of Danlou Tablet on Serum Uric Acid and Bilirubin in Patients with Acute Coronary Syndrome
Jin Huanliang
Qian Jia
Abstract：Objective To observe the effects of Danlou tablet (DLT)on serum uric acid and bilirubin in patients with acute coronary syndrome (ACS). Methods Forty-eight patients with ACS accept the treatment of percutaneous coronary intervention (PCI)were randomly divided into two groups:control group (n=24)treated with routine treatment,and treatment group (n=24)treated with routine treatment plus DLT for 3 months.The levels of serum high-sensitivity C-reactive protein (hs-CRP),bilirubin and uric acid were examined before and after 3 months of treatment. Results After 3 months of treatment,the levels of serum hs-CRP and uric acid in treatment group were lower than that in control group,while serum bilirubin level in treatment group was higher than that in control group (P<0.05). Conclusion DLT can increase the bilirubin level and decrease the uric acid level in patients with ACS.
Keywords：acute coronary syndromeDanlou tabletserum uric acidbilirubinChest Bi syndrome
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 451-453 )